Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sartorius Stedim BiotechCHIX:DIMP 82 EV-to-EBIT is 33.59 as of Jul. 28, 2026, which is 24% below its 10-year median of 44.45. GuruFocus rates CHIX:DIMP with a GF Score™ of 82/100 and a GF Value™ of €201.06 (Fairly Valued). The stock has 5 warning signs investors should review. Among 466 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks worse than 77.68% on this metric.
The historical rank and industry rank for Sartorius Stedim Biotech's EV-to-EBIT or its related term are showing as below:
CHIX:DIMp'
s EV-to-EBIT Range Over the Past 10 Years
Min: 23.2 Med: 44.45 Max: 80.91
Current: 33.54
During the past 13 years, the highest EV-to-EBIT of Sartorius Stedim Biotech was 80.91. The lowest was 23.20. And the median was 44.45.
CHIX:DIMp's EV-to-EBIT is ranked worse than 77.68% of 466
companies
in the Medical Devices & Instruments industry
Industry Median: 18.395
vs CHIX:DIMp: 33.54
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sartorius Stedim Biotech's Enterprise Value for the quarter that ended in Jun. 2026 was €19,809 Mil.
Sartorius Stedim Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €537 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech EV-to-EBIT Related Terms
Sartorius Stedim Biotech EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DIMP vs ISRG, BDX, MDLN: EV-to-EBIT Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's EV-to-EBIT falls into.
Sartorius Stedim Biotech's current Enterprise Value is €18,038 Mil.
Sartorius Stedim Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €537 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech (CHIX:DIMP) has a EV-to-EBIT of 33.59 as of Jul. 28, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sartorius Stedim Biotech and its competitors. This is 24% below median its historical median of 44.45. Over the past decade, Sartorius Stedim Biotech's EV-to-EBIT has ranged from 23.20 to 80.91. According to the industry distribution chart, Sartorius Stedim Biotech ranks #362 out of 466 companies in the Medical Devices & Instruments industry, placing it in the top 77.7%.
Is Sartorius Stedim Biotech's EV-to-EBIT too high?
Sartorius Stedim Biotech's current EV-to-EBIT of 33.59 is 24% below median its 10-year median of 44.45. Over the past 10 years, this metric has ranged from a low of 23.20 to a high of 80.91. The Medical Devices & Instruments industry median EV-to-EBIT is 18.40. Sartorius Stedim Biotech's value of 33.59 is 82.6% above this industry median. Based on the distribution chart, Sartorius Stedim Biotech ranks #362 out of 466 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sartorius Stedim Biotech has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #362 out of 466 companies for EV-to-EBIT. This places Sartorius Stedim Biotech in the lower half of its industry. The industry median EV-to-EBIT is 18.40. Sartorius Stedim Biotech's value of 33.59 is 82.6% above this benchmark. Historically, Sartorius Stedim Biotech's own EV-to-EBIT has ranged from 23.20 to 80.91 over the past decade. While the company's 10-year median is 44.45 vs. the industry median of 18.40, Sartorius Stedim Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.40, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current EV-to-EBIT of 33.59 is 82.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sartorius Stedim Biotech and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current EV-to-EBIT is 33.59, which is 24% below median its own 10-year median of 44.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Fairly Valued. The stock's GF Value™ is €201.06, compared to a current price of €187.40 — trading 6.8% below its estimated fair value. The current EV-to-EBIT is 33.59, which is 24% below median its 10-year median of 44.45 and 82.6% above the Medical Devices & Instruments industry median of 18.40. Sartorius Stedim Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current EV-to-EBIT is 33.59 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of €187.40 is trading 6.8% below its estimated GF Value™ of €201.06.
GuruFocus considers Sartorius Stedim Biotech to be Fairly Valued.
Key valuation signals for CHIX:DIMP:
EV-to-EBIT: 33.59 (24% below median its 10-year median of 44.45)
GF Value™: €201.06 vs. price of €187.40 (6.8% below fair value)
Industry Position: 82.6% above the Medical Devices & Instruments median (#362 of 466)
No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
82GF Score
Get the complete analysis for CHIX:DIMP
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIMP has been successfully added to your 
